Strattera reviews?

When Does Strattera Lose Patent Protection?
Strattera, with the generic name atomoxetine, is projected to lose its patent protection around the end of 2023 in the United States [1]. This timeline suggests that generic versions of the drug could become available shortly thereafter.

What is Strattera Used For?
Strattera is a medication prescribed for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children, adolescents, and adults [2]. It is not a stimulant and works by increasing the levels of norepinephrine, a neurotransmitter, in the brain [3].

How Does Strattera Work?
Atomoxetine, the active ingredient in Strattera, is a selective norepinephrine reuptake inhibitor. By blocking the reabsorption of norepinephrine, it increases the amount of this neurotransmitter available in the synaptic cleft, which is thought to help improve focus and attention in individuals with ADHD [3].

What Do Users Say About Strattera?
Patient experiences with Strattera can vary. Some individuals report positive outcomes, experiencing improvements in concentration and a reduction in impulsive or hyperactive behaviors [4]. Others may encounter side effects that lead them to discontinue the medication. Common side effects reported include nausea, decreased appetite, dizziness, and fatigue [3]. Some patients also note a delay in seeing full therapeutic effects, with benefits sometimes taking several weeks to become apparent [4].

Who Manufactures Strattera?
Strattera was originally developed by Eli Lilly and Company [1]. Following patent expiry, other pharmaceutical companies will likely manufacture generic versions of atomoxetine.

What is the Difference Between Strattera and Stimulant ADHD Medications?
Unlike stimulant medications such as Adderall or Ritalin, Strattera is a non-stimulant. Stimulants work by increasing both dopamine and norepinephrine in the brain, while Strattera primarily targets norepinephrine [3]. This difference means Strattera may be a suitable alternative for individuals who do not respond well to stimulants or who have contraindications to their use [2][3].

When Did Strattera Receive FDA Approval?
The U.S. Food and Drug Administration (FDA) approved Strattera in 2002 [1].

Sources:
[1] DrugPatentWatch.com
[2] National Institute of Mental Health
[3] U.S. Food and Drug Administration
[4] Patient forums and online reviews (general sentiment)